Add SubjectMark | Hide Original Post | Show Chart | Poster Summary |Provectus Pharmaceuticals Inc. | Stock Discussion Forums Share This Board

Moderated By: Jack Russell -- (Moderated) -- Started: 4/16/2006 9:15:35 PM  Revision History This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic. Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline includes: PV-10 For Metastatic Melanoma A Phase 2 clinical trial has been successfully completed, and preparations are underway for a Phase 3 randomized controlled study suitable for Special Protocol Assessment. Paths for accelerated approval for PV-10 to treat metastatic melanoma in the USA and abroad are being evaluated. PV-10 has received Orphan Drug Designation from the US FDA for the treatment of melanoma. PV-10 For Metastatic Liver Cancer A Phase 1 clinical trial is currently underway.PV-10 has received Orphan Drug Designation from the US FDA for the treatment of liver cancer. PV-10 For Recurrent Breast Cancer A Phase 1 clinical trial has been successfully completed.A Compassionate Use Program for PV-10 is being conducted as an expanded access study. Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis. PH-10 For Psoriasis A Phase 2 clinical trial has been successfully completed.A Phase 2c randomized clinical trial is currently underway. PH-10 For Atopic Dermatitis A Phase 2 clinical trial has been successfully completed. Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov. Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices. For further information, read detailed Research Reports ------------------------------------------------------------------------------------------------------------------------------------------------------ Provectus Pharmaceuticals Launches Free Mobile Investor Relations ApplicationThursday January 24, 2013KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, pvct.com  a development-stage oncology and dermatology biopharmaceutical company, has launched a free mobile shareholder investor relations application. The "Provectus IR" App is available for download from the App Store at www.itunes.com/appstore and from the Google Play Store at play.google.com  The investor relations application offers immediate portable access to the Company's latest news, financial information, presentations, and factsheet. ------------------------------------------------------------------------------------------------------------------------------------------------------- Provectus Web Presentation: HIGHLY RECOMMENDED VIEWING "Opening a new front in the war against Cancer" pvct.com  August 19, 2008 PV-10 for Melanoma Story Airs on ABC's 7:30 Report in Australia The 7:30 Report, a highly acclaimed ABC current affairs program airing in Australia, recently ran a story on the treatment of melanoma with PV-10. pvct.com  PVCT on YouTube... youtube.com  theze.cn  -------------------------------------------------------------- PVCT insiders transactions: secform4.com  -------------------------------------------------------------- Contact Info Our Contact Form Telephone: +1 (866) 594-5999 Fax: +1 (866) 998-0005 info@pvct.com Mailing Address: Provectus Pharmaceuticals, Inc. 7327 Oak Ridge Hwy Knoxville, TN 37931 USA • MAP Transfer Agent: (i.e. stockholder records, transfer, change of address, etc.) Broadridge Corporate Issuer Solutions, Inc. Laura Skorny 1717 Arch Street, Suite 1300 Philadelphia, PA 19103 E-mail: Laura.Skorny@Broadridge.com Telephone: +1 (610) 649-7300 Fax: +1 (610) 649-7302 Investor Relations: Porter, LeVay & Rose, Inc. Marlon A. Nurse Seven Penn Plaza New York, NY 10001 Telephone: 212-564-4700 Fax: 212-244-3075 marlon@plrinvest.com Media Relations: Porter, LeVay & Rose, Inc. Bill Gordon Seven Penn Plaza New York, NY 10001 Telephone: 212-564-4700 bill@plrinvest.com Investment Advisor: Network 1 Financial Securities Damon Testaverde Telephone: +1 (800) 205-8031 -------------------------------------------------------------- Company Website pvct.com  ==============================================================

Reply	Message Preview	From	Recs	Date
11978	dont forget to ask about per cycle and cumulative dose limits, and the frequency	NTTG	1	05/23/2013 01:42 PM
11977	I will look into it. I think all lesions will be treated but I'll check and	Mimbari	-	05/23/2013 01:38 PM
11976	What per cycle and cumulative PV-10 dose will they use in PIII trial? All visibl	NTTG	1	05/23/2013 12:24 PM
11975	Simple Question, I hope. What will a PIII cost?	dirkdiggler	1	05/23/2013 11:45 AM
11974	These past posts are some of the craziest things I have heard. Dosing: they know	Mimbari	2	05/23/2013 11:27 AM
11973	The kiss of death would be a single lesion no repeat injection protocol. Doubt t	NTTG	1	05/23/2013 10:26 AM
11972	nttg. the definition of a moot point. [not mute] usingenglish.com  which	Mammon	1	05/23/2013 10:20 AM
11971	I could not agree more that the 'bystander effect' is, and has been, a s	NTTG	1	05/23/2013 09:38 AM
11970	Once again thank you. In your opinion the dosing schedule is the most critical	LT2011	-	05/23/2013 09:35 AM
11969	They took a big step backward when stage IV and nodal stage III patients were ex	NTTG	1	05/23/2013 07:06 AM
11968	Of course it doesn't matter. NTTG is slightly confused...(no wonder he is wh	jm2i123	1	05/23/2013 06:35 AM